Bristol Myers Squibb (BMS) has secured another win for Opdivo (nivolumab), becoming the only FDA-approved PD-1 inhibitor for resectable non-small cell lung cancer NSCLC in both a neoadjuvant-only ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback